ArticleDiscover oncology2024

Pralatrexate represses the resistance of HCC cells to molecular targeted agents via the miRNA-34a/Notch pathway.

Yang Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.